Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”.